News & Articles

Dr. Jamie Frankish presented at ISCT Vancouver 2024. “Novel non-viral delivery technology, Solupore®, enables gene delivery for a healthier, more potent, and significantly more effective CAR-T therapy in vivo.”

The Advanced Therapies Week 2024 Miami, featured our own Dr. Lisa O’Flynn as a guest speaker at the Non-Viral Solutions for Gene Therapy Session.

Ann Brady

Avectas announces the appointment of Dr. Ann Brady as Chief Business Officer

Solupore

Avectas Launches the Solupore® Platform for the Clinical Manufacturing of Next- Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality

Bitmap

Avectas, CCRM and OmniaBio Expand their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE® Technology

Hand Holding Test Vial

Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors

DNA Strand

GenScript and Avectas Team Up to Improve the Non-Viral Cell Therapy Manufacturing Process

White Cells

AVECTAS leading the way in non-viral cell engineering technology

Genes Close Up

Killer cells: delivering a knockout blow to cancers

DNA Strand

Female -founded Irish tech companies raise record €105m

1 2